Guo HL, Qi YP, Zhang Q, Hao JJ, Yang Y, Zhang MY, He ZT. Relationship of TRAP1, HMGB1, and p62 expression with clinicopathologic features in colon cancer tissues. World J Gastrointest Oncol 2026; 18(8): 123088 [DOI: 10.4251/wjgo.123088]
Corresponding Author of This Article
Zhen-Tao He, MD, Academic Fellow, Department of General Surgery I, Third Affiliated Hospital of Qiqihar Medical University, No. 27 Taishun Street, Tiefeng District, Qiqihar 161000, Heilongjiang Province, China. hezhentao1983@qmu.edu.cn
Research Domain of This Article
Oncology
Article-Type of This Article
research-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Guo HL, Qi YP, Zhang Q, Hao JJ, Yang Y, Zhang MY, He ZT. Relationship of TRAP1, HMGB1, and p62 expression with clinicopathologic features in colon cancer tissues. World J Gastrointest Oncol 2026; 18(8): 123088 [DOI: 10.4251/wjgo.123088]
Hai-Long Guo, Department of Anorectal Surgery, Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, Heilongjiang Province, China
Yun-Peng Qi, Jian-Jun Hao, Yu Yang, Ming-Yang Zhang, Zhen-Tao He, Department of General Surgery I, Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, Heilongjiang Province, China
Qiang Zhang, Department of General Surgery III, Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, Heilongjiang Province, China
Author contributions: Guo HL and He ZT designed the study and performed the experiments; Qi YP, Yang Y, and Zhang MY collected the data; Zhang Q and Hao JJ analyzed the data; Guo HL prepared the manuscript. All authors read and approved the final manuscript.
AI contribution statement: No AI tool was involved in the generation of research data, interpretation of results, or formulation of conclusions. We only translated and polished the response to the reviewers.
Institutional review board statement: This study was approved by the Third Affiliated Hospital of Qiqihar Medical University, No. 2025LL-85.
Informed consent statement: Written informed consent was obtained from all participants or their legal representatives prior to enrollment in the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data which support the result of this study can be obtained from the corresponding author when reasonable request is made.
Corresponding author: Zhen-Tao He, MD, Academic Fellow, Department of General Surgery I, Third Affiliated Hospital of Qiqihar Medical University, No. 27 Taishun Street, Tiefeng District, Qiqihar 161000, Heilongjiang Province, China. hezhentao1983@qmu.edu.cn
Received: May 9, 2026 Revised: June 8, 2026 Accepted: July 28, 2026 Published online: August 15, 2026 Processing time: 89 Days and 16.6 Hours
Core Tip
Core Tip: This study investigated the expression of TRAP1, HMGB1, and p62 in colon cancer tissues, all of which were significantly upregulated compared with adjacent normal mucosa at both protein and mRNA levels. Their high expressions were closely associated with adverse clinicopathological features including poor differentiation, lymph node metastasis, and advanced TNM stage. TRAP1 was identified as an independent predictor for lymph node metastasis and poor overall survival, showing superior prognostic value. HMGB1 also independently predicted lymph node metastasis, while p62 was correlated with tumor progression but lacked independent prognostic significance. These findings suggest that TRAP1, HMGB1, and p62 serve as promising biomarkers for colon cancer, with TRAP1 being particularly valuable for prognostic assessment.
